Literature DB >> 9266395

Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome.

A van Rooij1, A A Nijenhuis, F A Wijburg, R B Schutgens.   

Abstract

The Smith-Lemli-Opitz syndrome is a genetic disorder characterized by typical clinical features including reduced myelination of both brain and peripheral nervous system and defective cholesterol biosynthesis. In patients this results in very low cholesterol concentrations and accumulation of cholesterol precursors in plasma, tissues, cultured cells and faeces. We now show that the cholesterol concentration in CSF of Smith-Lemli-Opitz patients is markedly decreased and that 7- and 8-dehydrocholesterol concentrations are highly increased in comparison to controls. Moreover, dietary treatment of patients with cholesterol seems not to affect CSF cholesterol concentration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266395     DOI: 10.1023/a:1005355026186

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  A NEWLY RECOGNIZED SYNDROME OF MULTIPLE CONGENITAL ANOMALIES.

Authors:  D W SMITH; L LEMLI; J M OPITZ
Journal:  J Pediatr       Date:  1964-02       Impact factor: 4.406

2.  Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome.

Authors:  M Irons; E R Elias; G Salen; G S Tint; A K Batta
Journal:  Lancet       Date:  1993-05-29       Impact factor: 79.321

3.  Defective conversion of 7-dehydrocholesterol to cholesterol in cultured skin fibroblasts from Smith-Lemli-Opitz syndrome homozygotes.

Authors:  A Honda; G S Tint; G Salen; A K Batta; T S Chen; S Shefer
Journal:  J Lipid Res       Date:  1995-07       Impact factor: 5.922

4.  First trimester prenatal diagnosis of Smith-Lemli-Opitz syndrome (7-dehydrocholesterol reductase deficiency).

Authors:  K Mills; H Mandel; R Montemagno; P Soothill; R Gershoni-Baruch; P T Clayton
Journal:  Pediatr Res       Date:  1996-05       Impact factor: 3.756

5.  Identification of 8-dehydrocholesterol (cholesta-5,8-dien-3 beta-ol) in patients with Smith-Lemli-Opitz syndrome.

Authors:  A K Batta; G S Tint; S Shefer; D Abuelo; G Salen
Journal:  J Lipid Res       Date:  1995-04       Impact factor: 5.922

6.  Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome.

Authors:  G S Tint; M Irons; E R Elias; A K Batta; R Frieden; T S Chen; G Salen
Journal:  N Engl J Med       Date:  1994-01-13       Impact factor: 91.245

7.  Identification of a yeast artificial chromosome clone spanning a translocation breakpoint at 7q32.1 in a Smith-Lemli-Opitz syndrome patient.

Authors:  T L Alley; B A Gray; S H Lee; S W Scherer; L C Tsui; G S Tint; C A Williams; R Zori; M R Wallace
Journal:  Am J Hum Genet       Date:  1995-06       Impact factor: 11.025

8.  Correlation of severity and outcome with plasma sterol levels in variants of the Smith-Lemli-Opitz syndrome.

Authors:  G S Tint; G Salen; A K Batta; S Shefer; M Irons; E R Elias; D N Abuelo; V P Johnson; M Lambert; R Lutz
Journal:  J Pediatr       Date:  1995-07       Impact factor: 4.406

9.  Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts.

Authors:  R I Kelley
Journal:  Clin Chim Acta       Date:  1995-04-30       Impact factor: 3.786

  9 in total
  2 in total

Review 1.  Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders.

Authors:  Melissa D Svoboda; Jill M Christie; Yasemen Eroglu; Kurt A Freeman; Robert D Steiner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-10-05       Impact factor: 3.908

2.  Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene.

Authors:  H R Waterham; F A Wijburg; R C Hennekam; P Vreken; B T Poll-The; L Dorland; M Duran; P E Jira; J A Smeitink; R A Wevers; R J Wanders
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.